The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
But BeOne canned its alcestobart deal in May.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
